Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 2

Status

Terminated 5Withdrawn 2Recruiting 2Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 1Gynecologic 1Endocrine 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Endometrial Neoplasms 1Breast Neoplasms, Male 1

Interventions

Cyclophosphamide 739Cisplatin 687Gemcitabine 641Bevacizumab 615Carboplatin 604Paclitaxel 600Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 360Capecitabine 342Filgrastim 333Etoposide 328Dexamethasone 312Irinotecan 309pembrolizumab 279Leucovorin 274Cetuximab 267Cytarabine 242Erlotinib Hydrochloride 231Prednisone 227Nivolumab 227Trastuzumab 225Bortezomib 221Vincristine 220Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Completed × TIC10 compound × Clear all
NCT03034200 2024-11-26

Phase 2 Study of ONC201 in Neuroendocrine Tumors

Case Comprehensive Cancer Center

Phase 2 Completed
30 enrolled 12 charts
EndocrineNET

Neuroendocrine Tumors

NCT03394027 2022-08-23

ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
30 enrolled 15 charts
BreastGynecologic

Neoplasm Metastasis, Endometrial Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡